The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CAR-T Cell Immunotherapies for Cancer Market Research Report 2025
Synopsis
The global CAR-T Cell Immunotherapies for Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CAR-T Cell Immunotherapies for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Cell Immunotherapies for Cancer.
Report Scope
The CAR-T Cell Immunotherapies for Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CAR-T Cell Immunotherapies for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR-T Cell Immunotherapies for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
NOVARTIS
Penn
Fosun Pharma
Celgene Corporation
Legend Biotech
SHEBA
JW Therapeutics
Protheragen
EXUMA Biotechnology
Segment by Type
CD19
BCMA
EPCAM
Segment by Application
Hematological Cancer
Solid Tumor
Other Oncological Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR-T Cell Immunotherapies for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global CAR-T Cell Immunotherapies for Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CAR-T Cell Immunotherapies for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Cell Immunotherapies for Cancer.
Report Scope
The CAR-T Cell Immunotherapies for Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CAR-T Cell Immunotherapies for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR-T Cell Immunotherapies for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
NOVARTIS
Penn
Fosun Pharma
Celgene Corporation
Legend Biotech
SHEBA
JW Therapeutics
Protheragen
EXUMA Biotechnology
Segment by Type
CD19
BCMA
EPCAM
Segment by Application
Hematological Cancer
Solid Tumor
Other Oncological Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR-T Cell Immunotherapies for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CD19
1.2.3 BCMA
1.2.4 EPCAM
1.3 Market by Application
1.3.1 Global CAR-T Cell Immunotherapies for Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hematological Cancer
1.3.3 Solid Tumor
1.3.4 Other Oncological Disorders
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR-T Cell Immunotherapies for Cancer Market Perspective (2019-2030)
2.2 CAR-T Cell Immunotherapies for Cancer Growth Trends by Region
2.2.1 Global CAR-T Cell Immunotherapies for Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 CAR-T Cell Immunotherapies for Cancer Historic Market Size by Region (2019-2024)
2.2.3 CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Region (2025-2030)
2.3 CAR-T Cell Immunotherapies for Cancer Market Dynamics
2.3.1 CAR-T Cell Immunotherapies for Cancer Industry Trends
2.3.2 CAR-T Cell Immunotherapies for Cancer Market Drivers
2.3.3 CAR-T Cell Immunotherapies for Cancer Market Challenges
2.3.4 CAR-T Cell Immunotherapies for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR-T Cell Immunotherapies for Cancer Players by Revenue
3.1.1 Global Top CAR-T Cell Immunotherapies for Cancer Players by Revenue (2019-2024)
3.1.2 Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Players (2019-2024)
3.2 Global CAR-T Cell Immunotherapies for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CAR-T Cell Immunotherapies for Cancer Revenue
3.4 Global CAR-T Cell Immunotherapies for Cancer Market Concentration Ratio
3.4.1 Global CAR-T Cell Immunotherapies for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR-T Cell Immunotherapies for Cancer Revenue in 2023
3.5 CAR-T Cell Immunotherapies for Cancer Key Players Head office and Area Served
3.6 Key Players CAR-T Cell Immunotherapies for Cancer Product Solution and Service
3.7 Date of Enter into CAR-T Cell Immunotherapies for Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR-T Cell Immunotherapies for Cancer Breakdown Data by Type
4.1 Global CAR-T Cell Immunotherapies for Cancer Historic Market Size by Type (2019-2024)
4.2 Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Type (2025-2030)
5 CAR-T Cell Immunotherapies for Cancer Breakdown Data by Application
5.1 Global CAR-T Cell Immunotherapies for Cancer Historic Market Size by Application (2019-2024)
5.2 Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)
6.2 North America CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024)
6.4 North America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)
7.2 Europe CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024)
7.4 Europe CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)
8.2 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)
9.2 Latin America CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024)
9.4 Latin America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)
10.2 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 NOVARTIS
11.1.1 NOVARTIS Company Detail
11.1.2 NOVARTIS Business Overview
11.1.3 NOVARTIS CAR-T Cell Immunotherapies for Cancer Introduction
11.1.4 NOVARTIS Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
11.1.5 NOVARTIS Recent Development
11.2 Penn
11.2.1 Penn Company Detail
11.2.2 Penn Business Overview
11.2.3 Penn CAR-T Cell Immunotherapies for Cancer Introduction
11.2.4 Penn Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
11.2.5 Penn Recent Development
11.3 Fosun Pharma
11.3.1 Fosun Pharma Company Detail
11.3.2 Fosun Pharma Business Overview
11.3.3 Fosun Pharma CAR-T Cell Immunotherapies for Cancer Introduction
11.3.4 Fosun Pharma Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
11.3.5 Fosun Pharma Recent Development
11.4 Celgene Corporation
11.4.1 Celgene Corporation Company Detail
11.4.2 Celgene Corporation Business Overview
11.4.3 Celgene Corporation CAR-T Cell Immunotherapies for Cancer Introduction
11.4.4 Celgene Corporation Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
11.4.5 Celgene Corporation Recent Development
11.5 Legend Biotech
11.5.1 Legend Biotech Company Detail
11.5.2 Legend Biotech Business Overview
11.5.3 Legend Biotech CAR-T Cell Immunotherapies for Cancer Introduction
11.5.4 Legend Biotech Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
11.5.5 Legend Biotech Recent Development
11.6 SHEBA
11.6.1 SHEBA Company Detail
11.6.2 SHEBA Business Overview
11.6.3 SHEBA CAR-T Cell Immunotherapies for Cancer Introduction
11.6.4 SHEBA Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
11.6.5 SHEBA Recent Development
11.7 JW Therapeutics
11.7.1 JW Therapeutics Company Detail
11.7.2 JW Therapeutics Business Overview
11.7.3 JW Therapeutics CAR-T Cell Immunotherapies for Cancer Introduction
11.7.4 JW Therapeutics Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
11.7.5 JW Therapeutics Recent Development
11.8 Protheragen
11.8.1 Protheragen Company Detail
11.8.2 Protheragen Business Overview
11.8.3 Protheragen CAR-T Cell Immunotherapies for Cancer Introduction
11.8.4 Protheragen Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
11.8.5 Protheragen Recent Development
11.9 EXUMA Biotechnology
11.9.1 EXUMA Biotechnology Company Detail
11.9.2 EXUMA Biotechnology Business Overview
11.9.3 EXUMA Biotechnology CAR-T Cell Immunotherapies for Cancer Introduction
11.9.4 EXUMA Biotechnology Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
11.9.5 EXUMA Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of CD19
Table 3. Key Players of BCMA
Table 4. Key Players of EPCAM
Table 5. Global CAR-T Cell Immunotherapies for Cancer Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global CAR-T Cell Immunotherapies for Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global CAR-T Cell Immunotherapies for Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global CAR-T Cell Immunotherapies for Cancer Market Share by Region (2019-2024)
Table 9. Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global CAR-T Cell Immunotherapies for Cancer Market Share by Region (2025-2030)
Table 11. CAR-T Cell Immunotherapies for Cancer Market Trends
Table 12. CAR-T Cell Immunotherapies for Cancer Market Drivers
Table 13. CAR-T Cell Immunotherapies for Cancer Market Challenges
Table 14. CAR-T Cell Immunotherapies for Cancer Market Restraints
Table 15. Global CAR-T Cell Immunotherapies for Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global CAR-T Cell Immunotherapies for Cancer Market Share by Players (2019-2024)
Table 17. Global Top CAR-T Cell Immunotherapies for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Cell Immunotherapies for Cancer as of 2023)
Table 18. Ranking of Global Top CAR-T Cell Immunotherapies for Cancer Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by CAR-T Cell Immunotherapies for Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players CAR-T Cell Immunotherapies for Cancer Product Solution and Service
Table 22. Date of Enter into CAR-T Cell Immunotherapies for Cancer Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global CAR-T Cell Immunotherapies for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Type (2019-2024)
Table 26. Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Type (2025-2030)
Table 28. Global CAR-T Cell Immunotherapies for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Application (2019-2024)
Table 30. Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Application (2025-2030)
Table 32. North America CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 47. NOVARTIS Company Detail
Table 48. NOVARTIS Business Overview
Table 49. NOVARTIS CAR-T Cell Immunotherapies for Cancer Product
Table 50. NOVARTIS Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)
Table 51. NOVARTIS Recent Development
Table 52. Penn Company Detail
Table 53. Penn Business Overview
Table 54. Penn CAR-T Cell Immunotherapies for Cancer Product
Table 55. Penn Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)
Table 56. Penn Recent Development
Table 57. Fosun Pharma Company Detail
Table 58. Fosun Pharma Business Overview
Table 59. Fosun Pharma CAR-T Cell Immunotherapies for Cancer Product
Table 60. Fosun Pharma Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)
Table 61. Fosun Pharma Recent Development
Table 62. Celgene Corporation Company Detail
Table 63. Celgene Corporation Business Overview
Table 64. Celgene Corporation CAR-T Cell Immunotherapies for Cancer Product
Table 65. Celgene Corporation Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)
Table 66. Celgene Corporation Recent Development
Table 67. Legend Biotech Company Detail
Table 68. Legend Biotech Business Overview
Table 69. Legend Biotech CAR-T Cell Immunotherapies for Cancer Product
Table 70. Legend Biotech Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)
Table 71. Legend Biotech Recent Development
Table 72. SHEBA Company Detail
Table 73. SHEBA Business Overview
Table 74. SHEBA CAR-T Cell Immunotherapies for Cancer Product
Table 75. SHEBA Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)
Table 76. SHEBA Recent Development
Table 77. JW Therapeutics Company Detail
Table 78. JW Therapeutics Business Overview
Table 79. JW Therapeutics CAR-T Cell Immunotherapies for Cancer Product
Table 80. JW Therapeutics Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)
Table 81. JW Therapeutics Recent Development
Table 82. Protheragen Company Detail
Table 83. Protheragen Business Overview
Table 84. Protheragen CAR-T Cell Immunotherapies for Cancer Product
Table 85. Protheragen Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)
Table 86. Protheragen Recent Development
Table 87. EXUMA Biotechnology Company Detail
Table 88. EXUMA Biotechnology Business Overview
Table 89. EXUMA Biotechnology CAR-T Cell Immunotherapies for Cancer Product
Table 90. EXUMA Biotechnology Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)
Table 91. EXUMA Biotechnology Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CAR-T Cell Immunotherapies for Cancer Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global CAR-T Cell Immunotherapies for Cancer Market Share by Type: 2023 VS 2030
Figure 3. CD19 Features
Figure 4. BCMA Features
Figure 5. EPCAM Features
Figure 6. Global CAR-T Cell Immunotherapies for Cancer Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global CAR-T Cell Immunotherapies for Cancer Market Share by Application: 2023 VS 2030
Figure 8. Hematological Cancer Case Studies
Figure 9. Solid Tumor Case Studies
Figure 10. Other Oncological Disorders Case Studies
Figure 11. CAR-T Cell Immunotherapies for Cancer Report Years Considered
Figure 12. Global CAR-T Cell Immunotherapies for Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global CAR-T Cell Immunotherapies for Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global CAR-T Cell Immunotherapies for Cancer Market Share by Region: 2023 VS 2030
Figure 15. Global CAR-T Cell Immunotherapies for Cancer Market Share by Players in 2023
Figure 16. Global Top CAR-T Cell Immunotherapies for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Cell Immunotherapies for Cancer as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by CAR-T Cell Immunotherapies for Cancer Revenue in 2023
Figure 18. North America CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America CAR-T Cell Immunotherapies for Cancer Market Share by Country (2019-2030)
Figure 20. United States CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe CAR-T Cell Immunotherapies for Cancer Market Share by Country (2019-2030)
Figure 24. Germany CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Share by Region (2019-2030)
Figure 32. China CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America CAR-T Cell Immunotherapies for Cancer Market Share by Country (2019-2030)
Figure 40. Mexico CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Share by Country (2019-2030)
Figure 44. Turkey CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. NOVARTIS Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
Figure 47. Penn Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
Figure 48. Fosun Pharma Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
Figure 49. Celgene Corporation Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
Figure 50. Legend Biotech Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
Figure 51. SHEBA Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
Figure 52. JW Therapeutics Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
Figure 53. Protheragen Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
Figure 54. EXUMA Biotechnology Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
